Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14


Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.

Meaney CJ, Beccari MV, Yang Y, Zhao J.

Pharmacotherapy. 2017 Apr;37(4):401-411. doi: 10.1002/phar.1906. Epub 2017 Mar 10. Review.


Taking a Second Look at Kayexalate.

Malone DJ.

Hosp Pharm. 2015 Nov;50(11):959-60. doi: 10.1310/hpj5011-959. Epub 2015 Nov 24. No abstract available.


Updates in hyperkalemia: Outcomes and therapeutic strategies.

Kovesdy CP.

Rev Endocr Metab Disord. 2017 Mar;18(1):41-47. doi: 10.1007/s11154-016-9384-x. Review.


Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

Chaitman M, Dixit D, Bridgeman MB.

P T. 2016 Jan;41(1):43-50.


Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.

Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL.

Kidney Int. 2015 Dec;88(6):1427-1433. doi: 10.1038/ki.2015.270. Epub 2015 Sep 16.


Effectiveness of Sodium Polystyrene Sulfonate for Short-Term Treatment of Hyperkalemia.

Batterink J, Lin J, Au-Yeung SH, Cessford T.

Can J Hosp Pharm. 2015 Jul-Aug;68(4):296-303.


Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.

Anker SD, Kosiborod M, Zannad F, PiƱa IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P.

Eur J Heart Fail. 2015 Oct;17(10):1050-6. doi: 10.1002/ejhf.300. Epub 2015 Jun 16.


A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.

Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS.

Kidney Int. 2015 Aug;88(2):404-11. doi: 10.1038/ki.2014.382. Epub 2015 Feb 4.


Potassium-binding resins: Associations with serum chemistries and interdialytic weight gain in hemodialysis patients.

Jadoul M, Karaboyas A, Goodkin DA, Tentori F, Li Y, Labriola L, Robinson BM.

Am J Nephrol. 2014;39(3):252-9. doi: 10.1159/000360094. Epub 2014 Mar 8.


To bind or to let loose: effectiveness of sodium polystyrene sulfonate in decreasing serum potassium.

Sandal S, Karachiwala H, Noviasky J, Wang D, Elliott WC, Lehmann DF.

Int J Nephrol. 2012;2012:940320. doi: 10.1155/2012/940320. Epub 2012 Dec 27.


Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol.

McGowan CE, Saha S, Chu G, Resnick MB, Moss SF.

South Med J. 2009 May;102(5):493-7. doi: 10.1097/SMJ.0b013e31819e8978.


Hyperkalemia revisited.

Parham WA, Mehdirad AA, Biermann KM, Fredman CS.

Tex Heart Inst J. 2006;33(1):40-7. Review.


Dietary management of end-stage uremia.

Rubini ME, Kopple JD.

Bull N Y Acad Med. 1970 Oct;46(10):850-68. No abstract available.

Supplemental Content

Support Center